tetano
Editor, Senior Moderator
PlosOne
Andreas Leibbrandt1*, Christiane Meier1, Marielle K?nig-Schuster1, Regina Weinm?llner1, Donata Kalthoff2, Bettina Pflugfelder1, Philipp Graf1, Britta Frank-Gehrke1, Martin Beer2, Tamas Fazekas3, Hermann Unger4, Eva Prieschl-Grassauer1, Andreas Grassauer1
1 Marinomed Biotechnologie GmbH, Vienna, Austria, 2 Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Bundesforschungsinstitut f?r Tiergesundheit, Greifswald-Insel Riems, Germany, 3 St. Anna Children's Hospital, Vienna, Austria, 4 Laboratory of Tropical Veterinary Medicine, Veterinary University Vienna, Vienna, Austria
Abstract Top
The 2009 flu pandemic and the appearance of oseltamivir-resistant H1N1 influenza strains highlight the need for treatment alternatives. One such option is the creation of a protective physical barrier in the nasal cavity. In vitro tests demonstrated that iota-carrageenan is a potent inhibitor of influenza A virus infection, most importantly also of pandemic H1N1/2009 in vitro. Consequently, we tested a commercially available nasal spray containing iota-carrageenan in an influenza A mouse infection model. Treatment of mice infected with a lethal dose of influenza A PR8/34 H1N1 virus with iota-carrageenan starting up to 48 hours post infection resulted in a strong protection of mice similar to mice treated with oseltamivir. Since alternative treatment options for influenza are rare, we conclude that the nasal spray containing iota-carrageenan is an alternative to neuraminidase inhibitors and should be tested for prevention and treatment of influenza A in clinical trials in humans.
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0014320
Andreas Leibbrandt1*, Christiane Meier1, Marielle K?nig-Schuster1, Regina Weinm?llner1, Donata Kalthoff2, Bettina Pflugfelder1, Philipp Graf1, Britta Frank-Gehrke1, Martin Beer2, Tamas Fazekas3, Hermann Unger4, Eva Prieschl-Grassauer1, Andreas Grassauer1
1 Marinomed Biotechnologie GmbH, Vienna, Austria, 2 Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Bundesforschungsinstitut f?r Tiergesundheit, Greifswald-Insel Riems, Germany, 3 St. Anna Children's Hospital, Vienna, Austria, 4 Laboratory of Tropical Veterinary Medicine, Veterinary University Vienna, Vienna, Austria
Abstract Top
The 2009 flu pandemic and the appearance of oseltamivir-resistant H1N1 influenza strains highlight the need for treatment alternatives. One such option is the creation of a protective physical barrier in the nasal cavity. In vitro tests demonstrated that iota-carrageenan is a potent inhibitor of influenza A virus infection, most importantly also of pandemic H1N1/2009 in vitro. Consequently, we tested a commercially available nasal spray containing iota-carrageenan in an influenza A mouse infection model. Treatment of mice infected with a lethal dose of influenza A PR8/34 H1N1 virus with iota-carrageenan starting up to 48 hours post infection resulted in a strong protection of mice similar to mice treated with oseltamivir. Since alternative treatment options for influenza are rare, we conclude that the nasal spray containing iota-carrageenan is an alternative to neuraminidase inhibitors and should be tested for prevention and treatment of influenza A in clinical trials in humans.
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0014320